Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Carcinoma, Adenoid Cystic 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11Bortezomib 8Filgrastim 7fludarabine 6Vorinostat 6Etoposide 6tanespimycin 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Doxorubicin 5Busulfan 5aldesleukin 4Vincristine 4Tacrolimus 4Paclitaxel 4Lenalidomide 4Gemcitabine 4sargramostim 3nelarabine 3Whole-Body Irradiation 3Topotecan 3Leucovorin 3Irinotecan 3Fluorouracil 3Everolimus 3Dexamethasone 3Dasatinib 3Cytarabine 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × BMS-906024 × Clear all
NCT01363817 2019-07-30

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
31 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡